$38.62▼ 0.86 (2.18%)
Real-time prices · US MarketsClean balance sheet with low leverage (0.0× debt-to-equity).
low return on equity (-65%).
Quality
1.6
Health
8.7
Growth
5.1
Valuation
4.7
Sentiment
7.4
Analyst Target
$46.88
▲ +21.4% from current
Price Chart
Latest News
- Immunovant Insider Sold Shares Worth $263,015, According to a Recent SEC Filing
- Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
- Roivant Sciences Insider Sold Shares Worth $6,631,268, According to a Recent SEC Filing
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-18.1×
next 12 months est.
Market Cap
$7.9B
market capitalization
Div Yield
—
dividend yield
Profit Margin
0.0%
net profit margin
Gross Margin
0.0%
revenue minus COGS
ROE
-64.8%
return on equity
Beta
0.77
vs S&P 500
52-Week Range
$14 — $41
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Immunovant, Inc. right now?
Immunovant, Inc.'s Q·Score is 5.2/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.0× debt-to-equity). Key area to monitor: low return on equity (-65%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for IMVT?
The consensus price target for IMVT is $46.88, based on ratings from 16 Wall Street analysts. This is 21.4% above the current price of $38.62. Price targets are forward-looking estimates and not guarantees of future performance.
Is IMVT overvalued or undervalued?
Immunovant, Inc. (IMVT) scores below peers on valuation metrics, trading above typical sector multiples. The consensus analyst price target of $46.88 is 21% above the current price.
When does Immunovant, Inc. report its next earnings?
Immunovant, Inc. is scheduled to report earnings in 5 days, on August 6, 2026.
What is Immunovant, Inc.'s profit margin?
Immunovant, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.
How much debt does Immunovant, Inc. have?
Immunovant, Inc. has a debt-to-equity ratio of 0.00×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 9.09×, indicating comfortable short-term liquidity.